Growth Drivers
What could change its growth trajectory, and what would confirm it?
Micro-gRx's growth could change if the microgravity biomanufacture of high-purity, scalable cell-free nanomedicines that the International Space Station National Laboratory listed among the eight early-stage startups selected for the 2026 Orbital Edge Accelerator program on August 12, 2026 proves out against the inconsistent manufacturing that Micro-gRx identifies as the biggest barrier in regenerative therapies today, a barrier that blocks its regenerative therapies for heart disease.
The ultimate goal of Micro-gRx's study is to use muscle tissue chips to test for improved human response to medicines that may counter muscle decline and disease and reduce reliance on animal studies.
Risk Factors
Which risks could break the thesis, and what would warn of them?
Micro-gRx's selection for the Orbital Edge Accelerator carries no committed funding and no reserved seat on a flight to the International Space Station; any investment depends on closing agreements with program partners on pre-established terms, and an ISS flight depends on a project proposal that CASIS reviews and approves.
On August 12, 2026, the ISS National Laboratory named eight early-stage startups for the 2026 Orbital Edge Accelerator, a program that offers each selected startup time in low Earth orbit for research and technology development plus $500,000 to $750,000 in private capital funding per startup. NASA missions delivered Micro-gRx experiments to the station in 2014, 2016, 2018, 2020, and 2022.
Product Overview
What does the product do for its buyer, and how is it delivered?
Micro-gRx provides human biology researchers with custom microfluidic systems it designs and manufactures, carrying a design from 3D printed design and microfluidic chip production through electric stimulation testing of muscle tissue to custom fitting into payload hardware, for human biology research and evaluation on Earth and in space.
The microgravity investigation of the human muscle chip employs Micro-gRx's clear polymer chips to build three-dimensional microscale models of muscle fibers from human cells obtained from muscle biopsies of different adult populations.

